132 related articles for article (PubMed ID: 1958522)
1. The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity.
van Steenbrugge GJ; van Uffelen CJ; Bolt J; Schröder FH
J Steroid Biochem Mol Biol; 1991; 40(1-3):207-14. PubMed ID: 1958522
[TBL] [Abstract][Full Text] [Related]
2. The human prostatic carcinoma cell line LNCaP and its derivatives. An overview.
van Steenbrugge GJ; Groen M; van Dongen JW; Bolt J; van der Korput H; Trapman J; Hasenson M; Horoszewicz J
Urol Res; 1989; 17(2):71-7. PubMed ID: 2660395
[TBL] [Abstract][Full Text] [Related]
3. Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines.
Jongsma J; Oomen MH; Noordzij MA; Romijn JC; van Der Kwast TH; Schröder FH; van Steenbrugge GJ
Prostate; 2000 Jan; 42(1):34-44. PubMed ID: 10579797
[TBL] [Abstract][Full Text] [Related]
4. Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP.
Langeler EG; van Uffelen CJ; Blankenstein MA; van Steenbrugge GJ; Mulder E
Prostate; 1993; 23(3):213-23. PubMed ID: 7694266
[TBL] [Abstract][Full Text] [Related]
5. Androgen-dependent growth regulation of and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaP.
Berns EM; de Boer W; Mulder E
Prostate; 1986; 9(3):247-59. PubMed ID: 2946029
[TBL] [Abstract][Full Text] [Related]
6. Differential sensitivity of hormone-responsive and unresponsive human prostate cancer cells (LNCaP) to tumor necrosis factor.
Zhao X; van Steenbrugge GJ; Schröder FH
Urol Res; 1992; 20(3):193-7. PubMed ID: 1615580
[TBL] [Abstract][Full Text] [Related]
7. Androgens inhibit the proliferation of a variant of the human prostate cancer cell line LNCaP.
Joly-Pharaboz MO; Soave MC; Nicolas B; Mebarki F; Renaud M; Foury O; Morel Y; Andre JG
J Steroid Biochem Mol Biol; 1995 Oct; 55(1):67-76. PubMed ID: 7577722
[TBL] [Abstract][Full Text] [Related]
8. Variants of the human prostate LNCaP cell line as tools to study discrete components of the androgen-mediated proliferative response.
Soto AM; Lin TM; Sakabe K; Olea N; Damassa DA; Sonnenschein C
Oncol Res; 1995; 7(10-11):545-58. PubMed ID: 8866667
[TBL] [Abstract][Full Text] [Related]
9. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells.
Wu HC; Hsieh JT; Gleave ME; Brown NM; Pathak S; Chung LW
Int J Cancer; 1994 May; 57(3):406-12. PubMed ID: 8169003
[TBL] [Abstract][Full Text] [Related]
10. Enhanced androgen sensitivity in serum-free medium of a subline of the LNCaP human prostate cancer cell line.
Kirschenbaum A; Ren M; Levine AC
Steroids; 1993 Sep; 58(9):439-44. PubMed ID: 8236330
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
[TBL] [Abstract][Full Text] [Related]
12. Biological effects of sex hormone-binding globulin on androgen-induced proliferation and androgen metabolism in LNCaP prostate cells.
Damassa DA; Lin TM; Sonnenschein C; Soto AM
Endocrinology; 1991 Jul; 129(1):75-84. PubMed ID: 2055206
[TBL] [Abstract][Full Text] [Related]
13. Expression profiling of androgen-dependent and -independent LNCaP cells: EGF versus androgen signalling.
Oosterhoff JK; Grootegoed JA; Blok LJ
Endocr Relat Cancer; 2005 Mar; 12(1):135-48. PubMed ID: 15788645
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of androgen-independent growth of human prostate cancer LNCaP-AI cells.
Lu S; Tsai SY; Tsai MJ
Endocrinology; 1999 Nov; 140(11):5054-9. PubMed ID: 10537131
[TBL] [Abstract][Full Text] [Related]
15. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells.
Ripple MO; Henry WF; Rago RP; Wilding G
J Natl Cancer Inst; 1997 Jan; 89(1):40-8. PubMed ID: 8978405
[TBL] [Abstract][Full Text] [Related]
16. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
17. Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model.
Hobisch A; Hoffmann J; Lambrinidis L; Eder IE; Bartsch G; Klocker H; Culig Z
Urol Int; 2000; 65(2):73-9. PubMed ID: 11025427
[TBL] [Abstract][Full Text] [Related]
18. Androgen and taxol cause cell type-specific alterations of centrosome and DNA organization in androgen-responsive LNCaP and androgen-independent DU145 prostate cancer cells.
Schatten H; Ripple M; Balczon R; Weindruch R; Chakrabarti A; Taylor M; Hueser CN
J Cell Biochem; 2000 Jan; 76(3):463-77. PubMed ID: 10649443
[TBL] [Abstract][Full Text] [Related]
19. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation.
Kokontis J; Takakura K; Hay N; Liao S
Cancer Res; 1994 Mar; 54(6):1566-73. PubMed ID: 7511045
[TBL] [Abstract][Full Text] [Related]
20. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
